Xbrane Biopharma
0,149
SEK
+5,36 %
Mindre end 1K følgere
XBRANE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+5,36%
-13,14%
-7,09%
-13,14%
+4,77%
-89,46%
-98,7%
-95,99%
-96,08%
Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2014 and is headquartered in Solna, Sweden.
Læs mereMarkedsværdi
228,91 mio. SEK
Aktieomsætning
338,36 t SEK
Omsætning
198,72 mio.
EBIT %
-109,66 %
P/E
-
Udbytteafkast, %
-
Finanskalender
5.5
2025
Generalforsamling '25
8.5
2025
Delårsrapport Q1'25
27.8
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper

Xbrane Biopharma, Webcast with teleconference, Q4'24
Xbrane Biopharma releases Year-end Report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Invitation to presentation of Xbrane Biopharma’s Year-end report 2024 on February 20, 2025
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Xbrane announces outcome of exercise of warrants of series TO1
XBRANE BIOPHARMA'S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY
Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES
Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®
XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE
Redeye: Xbrane Biopharma Q3 2024 - Deal or no deal
